CDK4/6 inhibition in cancer: the cell cycle splicing connection

Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma. While investigating the mechanisms of CDK4/6 inhibitor resistance in melanoma, we uncovered a mechanism of action of these inhibitors in regulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheppard, Karen E., AbuHammad, Shatha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816418/
https://www.ncbi.nlm.nih.gov/pubmed/31692881
http://dx.doi.org/10.1080/23723556.2019.1673643
Descripción
Sumario:Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma. While investigating the mechanisms of CDK4/6 inhibitor resistance in melanoma, we uncovered a mechanism of action of these inhibitors in regulating the expression of both the mouse double minute 4 (MDM4) oncogene and tumor protein p53 (TP53).

Ejemplares similares